Cancer estimation of incidence and survival in Algeria 2014
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 9
Abstract
Cancer is one of the major public health problems in Algeria. In the last 25 years, a significant increase in the incidence of the major types of cancers has been observed in both sexes. Moreover, the 5-year survival rate is low for the severe tumors due to a difficulty in access to cancer care and an incomplete health care framework. Cancer Registry of Setif, Algeria, has been recording cancer incidence, mortality, and survival since 1986 in collaboration with International Agency for Research on Cancer (IARC) of Lyon. Cancer Registry of Setif is being a source of information for cancer planning and corresponding surveillance in the National Cancer Plan 2015-2019, starting in January 2015. Data is recorded by means of CanReg 5 software. This software is developed and provided by the International Agency for Research on Cancer (IARC) of Lyon. It is designed specifically for cancer registration, and standardized to capture, control, and process the data. Estimation of cancer incidence in Algeria and survival rates are very important for surveillance, control, and planning of care. In men the incidence of lung, colorectal, bladder, prostate, and laryngeal cancers has significantly and steadily increased in the last decade. In women, the incidence of breast, colorectal, thyroid, and lung cancers has also increased significantly in the same period. Five-year survival rates for cancer of the stomach, colon, rectum, liver, lung, breast, cervix, ovary, and prostate in adults, and childhood leukemia are relatively low compared with other countries. The aim of our study was to estimate incidence and survival by means of Setif cancer registry data.
Authors and Affiliations
Hamdi Cherif M, Bidoli E, Birri S, Mahnane A, Zaidi Z, Boukharouba H, Moussaoui H, Kara L, Ayat A, Makhloufi K, Bouchaibi I, Atoui . , Virdone S, Serraino D
Keywords
Related Articles
- EP ID EP546018
- DOI 10.14312/2052-4994.2015-14
- Views 57
- Downloads 0
Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis
Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demons...
30 years of preventive studies of uterine cervical cancer 1982-2012
Purpose: To show and describe the clinical evolution of cervical cancer screening patients following the protocol established by the University of Padua. Methods: 12,679 patients were examined using Pap smear, colposcopy...
Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb
Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Fo...
Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy
Diagnosis and therapy of cancer remain to be the greatest challenges for all physicians working in clinical oncology and molecular medicine. The grim statistics speak for themselves with reports of 1,638,910 men and wome...
Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay
In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...